title: Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.
abstract: OBJECTIVE
  Systemic exposure to rosuvastatin in Asian subjects living in Japan or Singapore is approximately twice that observed in Caucasian subjects in Western countries or in Singapore. This study was conducted to determine whether pharmacokinetic differences exist among the most populous Asian subgroups and Caucasian subjects in the USA.
  
  
  METHODS
  Rosuvastatin pharmacokinetics was studied in Chinese, Filipino, Asian-Indian, Korean, Vietnamese, Japanese and Caucasian subjects residing in California. Plasma concentrations of rosuvastatin and metabolites after a single 20-mg dose were determined by mass spectrometric detection. The influence of polymorphisms in SLCO1B1 (T521>C [Val174Ala] and A388>G [Asn130Asp]) and in ABCG2 (C421>A [Gln141Lys]) on exposure to rosuvastatin was also assessed.
  
  
  RESULTS
  The average rosuvastatin area under the curve from time zero to time of last quantifiable concentration was between 64 and 84 % higher, and maximum drug concentration was between 70 and 98 % higher in East Asian subgroups compared with Caucasians. Data for Asian-Indians was intermediate to these two ethnic groups at 26 and 29 %, respectively. Similar increases in exposure to N-desmethyl rosuvastatin and rosuvastatin lactone were observed. Rosuvastatin exposure was higher in subjects carrying the SLCO1B1 521C allele compared with that in non-carriers of this allele. Similarly, exposure was higher in subjects carrying the ABCG2 421A allele compared with that in non-carriers.
  
  
  CONCLUSIONS
  Plasma exposure to rosuvastatin and its metabolites was significantly higher in Asian populations residing in the USA compared with Caucasian subjects living in the same environment. This study suggests that polymorphisms in the SLCO1B1 and ABCG2 genes contribute to the variability in rosuvastatin exposure.
authors: AstraZeneca, Wilmington, DE, USA, bkbirm@comcast.net.
authors: Bruce K
authors: BK
authors: Birmingham
authors: Sarah R
authors: SR
authors: Bujac
authors: Robert
authors: R
authors: Elsby
authors: Connie T
authors: CT
authors: Azumaya
authors: Julie
authors: J
authors: Zalikowski
authors: Yusong
authors: Y
authors: Chen
authors: Kenneth
authors: K
authors: Kim
authors: Helen J
authors: HJ
authors: Ambrose
mesh_terms: D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000483:Alleles; D044466:Asian People / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D027381:Liver-Specific Organic Anion Transporter 1; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics; D027361:Organic Anion Transporters / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D000068718:Rosuvastatin Calcium / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D014481:United States; D044465:White People / Q000235:genetics*
chemical_list: C116614:ABCG2 protein, human; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D009363:Neoplasm Proteins; D027361:Organic Anion Transporters; C503999:SLCO1B1 protein, human; D000068718:Rosuvastatin Calcium
references: Drug Metab Rev. 2008;40(2):317-54
references: 18464048
references: Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):677-89
references: 22509899
references: Clin Pharmacol Ther. 2009 Aug;86(2):197-203
references: 19474787
references: Eur J Clin Pharmacol. 2015 Mar;71(3):341-55
references: 25673568
references: Clin Ther. 2003 Nov;25(11):2822-35
references: 14693307
references: Drug Metab Dispos. 2007 Apr;35(4):623-32
references: 17237154
references: Clin Pharmacol Ther. 2005 Oct;78(4):342-50
references: 16198653
references: Clin Pharmacol Ther. 2012 Nov;92 (5):584-98
references: 23047648
references: Clin Pharmacol Ther. 2003 Jun;73(6):554-65
references: 12811365
references: Clin Ther. 2003 Oct;25(10):2553-63
references: 14667956
references: Pharmacogenetics. 2004 Jul;14 (7):429-40
references: 15226675
references: Pharmacogenomics. 2013 Aug;14 (11):1283-94
references: 23930675
references: Clin Pharmacol Ther. 2005 Oct;78(4):330-41
references: 16198652
references: Clin Chim Acta. 2006 Nov;373(1-2):99-103
references: 16784736
references: Clin Ther. 2003 Aug;25(8):2215-24
references: 14512129
references: Pharmacogenetics. 2003 Jan;13(1):19-28
references: 12544509
references: Curr Med Res Opin. 2008 Sep;24(9):2575-85
references: 18674408
references: Clin Pharmacol Ther. 2008 Feb;83(2):251-7
references: 17568401
references: Clin Pharmacol Ther. 2005 Oct;78(4):311-6
references: 16198649
references: Gastroenterology. 2006 May;130(6):1793-806
references: 16697742
references: Clin Pharmacol Ther. 2010 Jan;87(1):130-3
references: 19890253
references: Br J Clin Pharmacol. 2002 Nov;54(5):472-7
references: 12445025
references: J Clin Pharmacol. 2002 Oct;42(10):1116-21
references: 12362926
references: Eur J Clin Pharmacol. 2002 Nov;58(8):527-31
references: 12451430
references: Pharm Res. 1996 Oct;13(10):1559-64
references: 8899851
references: Clin Pharmacol Ther. 2004 May;75(5):415-21
references: 15116054
references: Drug Metab Dispos. 2006 May;34(5):738-42
references: 16415124